SearchResearch
Beta
Hello! Describe your research question and I'll help you find matching datasets across 2,944 studies from AnVIL, BDC, CRDC, and KFDRC.

GWAS of Breast Events with Adjuvant Aromatase Inhibitors

Request Access

Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.

P. Goss, J. Ingle, K. Pritchard, et al. (2013). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Cited 242 times. https://doi.org/10.1200/JCO.2012.44.7805

Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.

J. Ingle, D. Schaid, P. Goss, et al. (2010). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Cited 204 times. https://doi.org/10.1200/JCO.2010.28.5064

Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy.

J. Ingle, Fang Xie, M. Ellis, et al. (2016). Cancer research. Cited 52 times. https://doi.org/10.1158/0008-5472.CAN-16-1371

Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics.

Mohan Liu, P. Goss, J. Ingle, et al. (2014). Molecular endocrinology. Cited 48 times. https://doi.org/10.1210/me.2014-1147